0HNZ.LSE Fagron NV

Healthcare Commercial Services & Supplies London Exchange
- EUR
Market cap
-
P/E
-
P/B
-
ROE
-
Dividend yield
1.12%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2023.

Is 0HNZ.LSE undervalued?

Graham number

The Graham number of Fagron NV cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Fagron NV fundamental analysis

No fundamental analysis for Fagron NV yet.

Fagron NV stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Fagron NV

Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide. It operates through three segments: Essentials, Brands, and Compounding Services. The company's products include DiluCap, a line of excipients to compound every capsule formulation; DiluTab, for Cardiology and Primary care application; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex …

Full company profile